Long‑term follow‑up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report

Park,Jung  Gil; Tak,Won  Young; Park,Soo  Young; Kweon,Young  Oh; Jang,Se  Young; Lee,Soo  Hyun; Lee,Yu  Rim; Jang,Sun  Kyung; Hur,Keun; Lee,Heon  Ju

doi:10.3892/ol.2017.6788

Long‑term follow‑up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report

Authors:
- Jung Gil Park
- Won Young Tak
- Soo Young Park
- Young Oh Kweon
- Se Young Jang
- Soo Hyun Lee
- Yu Rim Lee
- Sun Kyung Jang
- Keun Hur
- Heon Ju Lee
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu 41940, Republic of Korea, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41940, Republic of Korea, Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu 41940, Republic of Korea
Published online on: August 22, 2017 https://doi.org/10.3892/ol.2017.6788
Pages: 4853-4856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib is a tyrosine kinase inhibitor that has been demonstrated to improve the overall survival time of patients with advanced hepatocellular carcinoma (HCC). Although there have been a number of reports of patients achieving complete remission (CR) following sorafenib therapy, the long‑term clinical outcomes of these patients have yet to be ascertained. A 72‑year‑old male patient with chronic hepatitis C, diabetes, hypertension and an old cerebral infarction was referred for the evaluation of a liver mass identified on an abdominal ultrasound. Abdominal computed tomography (CT) demonstrated a 13‑cm mass replacing the right lobe of the liver, with portal vein thrombosis. HCC was confirmed by a percutaneous needle biopsy and treated with sorafenib. At 4 months, a follow‑up CT demonstrated no enhancing viable lesions in the tumor and recanalization of the portal vein. Sorafenib therapy was continued for 48 months until the patient experienced dyspnea due to congestive heart failure, with pleural effusion. Following the discontinuation of sorafenib, the patient's symptoms improved. The patient followed up without recurrence for 52 months. Subsequent to achieving CR through treatment with sorafenib, long‑term sorafenib therapy may be an option and efforts should be made to monitor cardiac toxicity during sorafenib therapy, particularly in high‑risk patients.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
3	European Association For The Study Of The Liver1; European Organisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
4	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
7	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ahn SY, Lee HS, Kweon YO, Tak WY and Park SY: Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy. Dig Dis Sci. 58:1428–1432. 2013. View Article : Google Scholar : PubMed/NCBI
9	Park JG: Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 21:287–294. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY and Chae MH: Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol. 5:38–42. 2013.PubMed/NCBI
11	Liu D, Liu A, Peng J, Hu Y and Feng X: Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. Eur J Med Res. 20:122015. View Article : Google Scholar : PubMed/NCBI
12	Bruix J and Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 35:519–254. 2002. View Article : Google Scholar : PubMed/NCBI
13	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
14	Cancer Therapy Evaluation Program 3 (1998) Common Toxicity Criteria. Version 2.0 DCTD, NCI, NIH, DHHS. Revised: 23. 1998.
15	Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST and Poon RT: The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 16:1270–1279. 2011. View Article : Google Scholar : PubMed/NCBI
16	Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T and Escudier B: Sorafenib TARGET Clinical Trial Group: Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. Eur J Cancer. 46:2432–2440. 2010. View Article : Google Scholar : PubMed/NCBI
17	Adjei AA, Blumenschein GR Jr, Mandrekar S, Hillman S, Gatzemeier U and Heigener D: Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: A case-based review. Clin Lung Cancer. 12:212–217. 2011. View Article : Google Scholar : PubMed/NCBI
18	Abdel-Rahman O and Fouad M: Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: An updated systematic review and meta-analysis. Future Oncol. 10:1981–1992. 2014. View Article : Google Scholar : PubMed/NCBI
19	Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M and Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 26:5204–5212. 2008. View Article : Google Scholar : PubMed/NCBI
20	Duran JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, Lal H, Sharp TE, Starosta T, Vagnozzi RJ, et al: Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res. 114:1700–1712. 2014. View Article : Google Scholar : PubMed/NCBI